Dorsey Wright & Associates Has $6.50 Million Stake in United Therapeutics Corporation $UTHR

Dorsey Wright & Associates grew its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 113.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,967 shares of the biotechnology company’s stock after purchasing an additional 5,839 shares during the period. Dorsey Wright & Associates’ holdings in United Therapeutics were worth $6,503,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sage Rhino Capital LLC raised its holdings in United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC grew its holdings in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 24 shares during the last quarter. Independent Advisor Alliance grew its holdings in United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 27 shares during the last quarter. Kera Capital Partners Inc. increased its position in United Therapeutics by 6.1% in the 1st quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock valued at $279,000 after acquiring an additional 27 shares during the period. Finally, Florida Financial Advisors LLC increased its position in United Therapeutics by 5.4% in the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 28 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Up 1.3%

UTHR opened at $535.67 on Friday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company has a market cap of $22.74 billion, a P/E ratio of 19.77, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. The company has a fifty day moving average price of $552.38 and a two-hundred day moving average price of $530.14.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the prior year, the business earned $6.63 earnings per share. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the topic of several recent research reports. Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. HC Wainwright increased their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Royal Bank Of Canada raised their price objective on United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Raymond James Financial began coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $644.82.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,808,586.36. The trade was a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 564,743 shares of company stock worth $316,423,257 over the last 90 days. 8.60% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.